This Week in 340B: November 19 – December 2, 2024
This weekly update highlights the dynamic and complex legal landscape surrounding the 340B Drug Pricing Program, emphasizing ongoing litigation that shapes industry standards. Key developments include challenges to the HRSA audit process and significant disputes regarding contract pharmacy arrangements in specific states. The article details various procedural motions, such as requests for temporary restraining orders and delays to coordinate with related cases. It also notes legal actions against HRSA’s regulatory decisions, including disapproved rebate models and Freedom of Information Act disputes, reflecting intense scrutiny of federal oversight mechanisms. This information is crucial for open data advocates and researchers monitoring healthcare policy, as it reveals how judicial outcomes directly impact data transparency and drug pricing regulations. Tracking these cases provides essential context for understanding the real-world implications of federal health programs and the legal pressures influencing policy enforcement.
Source: natlawreview.comPublished on 2024-12-05